2 October 2026
US health secretary RFK Jr sees AI in healthcare as a tool to put patients in charge. What this means for doctors and drugmakers.
30 September 2026
Buy now, pay later credit can now cover GLP-1 weight-loss drugs in SA, as Obiflex offers instalments for treatments costing R2,500–R6,000.
18 September 2026
Aspen's turnaround hinges on filling its underused sterile manufacturing plants, as GLP-1 sales drive a share recovery.
15 September 2026
The US healthcare affordability crisis is squeezing small employers the hardest, a mirror for local medical scheme debates.
8 September 2026
Aspen Pharmacare earnings rose 22% as demand for Eli Lilly's weight-loss drug Mounjaro surged, with the group also eyeing generic semaglutide.
25 August 2026
GLP-1 generics could cut obesity drug costs, challenge illegal sales and expand access as more semaglutide products seek approval.
27 May 2026
SAHPRA and SAPC launch an unregistered GLP-1 medicines crackdown, seizing GLP-1 products at a Pretoria pharmacy.
19 May 2026
GLP-1 Drugs In SA could spread as cheaper generics and oral pills arrive, changing food and alcohol demand and pushing premium health trends.
27 April 2026
Weight management spending in South Africa is rising fast as consumers pay for diet support, GLP-1 medicines and healthier food.
14 April 2026
GLP-1 weight loss medications are gaining traction in South Africa. Discover their potential impact on healthcare and FMCG trends.
23 March 2026
Learn how the advent of Generic Semaglutide in India will change the landscape of weight-loss and diabetes medications.
16 March 2026
Learn about potential Aspen Pharmacare asset disposals aimed at optimising the company's global operations for greater profitability.